

April 28, 2025

To: Philip Sell, Co-founder and CEO, Metaba LLC

From: Farhad Parhami, Ph.D., M.B.A.

Re: Ethics review of study entitled “Developing a novel oxysterol antibiotic to combat drug-resistant tuberculosis”

Dear Philip,

This letter is to inform you that our ethics review committee at MAX BioPharma, which oversees our collaborations involving vertebrate animals, has reviewed your submitted proposal referenced above for the examination of oxysterol antibiotic, Oxy291, in a mouse model of tuberculosis (TB). Your proposed studies and your standard operating procedures (SOP) that follow the guidelines of our Institutional Animal Care and Use Committee (IACUC) and the American Veterinary Medical Association (AVMA) for humane and ethical treatment of research animals have been approved.

We look forward to the successful accomplishment of the goals of your study. Please let me know if you have any questions.

Best Regards,



Farhad Parhami, Ph.D., M.B.A.  
Founder, President & CEO, MAX BioPharma Inc.  
Head, Institutional Care and Animal Use Committee